For example, in HER2-positive breast cancer, the loss of p21 expression is mediated through HER2/HER3 heterodimerization and associated with poor prognosis in patients treated with adjuvant trastuzumab [44]. This evidence concerns the gene ERBB2 and breast carcinoma.